The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) hit a new 52-week low and has $34.56 target or 8.00% below today’s $37.57 share price. The 9 months bearish chart indicates high risk for the $89.40 billion company. The 1-year low was reported on Dec, 1 by Barchart.com. If the $34.56 price target is reached, the company will be worth $7.15 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 981,491 shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 12.85% since April 28, 2016 and is downtrending. It has underperformed by 18.77% the S&P500.
Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on February, 1. They expect $0.63 EPS, up 14.55% or $0.08 from last year’s $0.55 per share. GSK’s profit will be $1.50B for 14.91 P/E if the $0.63 EPS becomes a reality. After $0.83 actual EPS reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts -24.10% negative EPS growth.
GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage
Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. $50 is the highest target while $40 is the lowest. The $47.50 average target is 26.43% above today’s ($37.57) stock price. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The stock has “Underperform” rating given by BNP Paribas on Wednesday, September 14. Piperjaffray initiated the stock with “Overweight” rating in Friday, September 23 report. The firm has “Buy” rating given on Friday, August 12 by Argus Research. Bank of America upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Wednesday, December 9 to “Buy” rating. The stock has “Hold” rating given by Cantor Fitzgerald on Friday, February 26. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Neutral” rating by Bank of America on Tuesday, September 8. The firm has “Buy” rating given on Wednesday, January 27 by Bryan Garnier & Cie. On Thursday, October 20 the stock rating was initiated by Investec with “Buy”. The rating was upgraded by Jefferies on Thursday, July 14 to “Buy”. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Neutral” rating given on Tuesday, October 20 by Credit Suisse.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”
More news for GlaxoSmithKline plc (ADR) (NYSE:GSK) were recently published by: Businessfinancenews.com, which released: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016. Businessfinancenews.com‘s article titled: “Can GlaxoSmithKline plc (ADR) Subsist Advair’s Patent Expiry” and published on June 25, 2016 is yet another important article.
GSK Company Profile
GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.